ZEVRA THERAPEUTICS INC (ZVRA)
US4884452065 - Common Stock
ZEVRA THERAPEUTICS INC
NASDAQ:ZVRA (12/20/2024, 8:00:02 PM)
After market: 8.72 +0.23 (+2.71%)8.49
-0.05 (-0.59%)
Company Profile
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. The company is headquartered in Celebration, Florida and currently employs 65 full-time employees. The company went IPO on 2015-04-16. The firm has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
Company Info
ZEVRA THERAPEUTICS INC
1180 Celebration Boulevard, Suite 103
Celebration FLORIDA
P: 13219393416
Employees: 65
Website: https://zevra.com/
ZVRA News
4 days ago - Zevra TherapeuticsZevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
15 days ago - Zevra TherapeuticsZevra Therapeutics Announces Organizational ChangesCELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
25 days ago - Zevra TherapeuticsZevra Therapeutics to Participate at Upcoming Investor ConferencesCELEBRATION, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
a month ago - Zevra TherapeuticsZevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type CMIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist™,...
a month ago - Zevra TherapeuticsZevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual MeetingData show that the NPCCSS swallow score reflects the patient’s level of dysfunction Study indicates that a change in score reflects actual improvement...
2 months ago - Zevra TherapeuticsZevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13CELEBRATION, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
ZVRA Twits
Here you can normally see the latest stock twits on ZVRA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
